Limiting Cost-sharing on Drugs: A Big PhRMA Objective from Health Reform
This article was originally published in RPM Report
Executive Summary
Preventing big out-of-pocket expenditures by patients for health services and pharmaceuticals may be the antidote to the toxic bad publicity for health reform during August. At least, PhRMA hopes so. The trade association is helping to support an AMA campaign against copays.
You may also be interested in...
The Real Obesity Drugs Hurdle: Paying for Them
Obesity drugs are readying for round two at FDA. But if ever approved, given the airing of safety issues at advisory committee meetings, who would pay for them?
Health Care Reform and Business Development: 10 Reasons It Matters
The drama of the US health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.
Health Care Reform and Business Development: 10 Reasons it Matters
The drama of the health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.